Issue of Equity

Akers Biosciences, Inc

("ABI" or "the Company")

Issue of Equity

The Board of Akers Biosciences, Inc (AIM: AKR) today announces that pursuant to the payment of shares in lieu of fees, the Company has issued and allotted 310,344 Common Shares of no par value ("new shares").

Accordingly, application has been made for 310,344 new shares to be admitted to trading on AIM and it is expected that admission will take place on 18 November 2010.

The new shares will rank pari passu with the existing shares of the Company and, following admission, the total issued share capital of the Company will comprise 114,715,666 Common shares of no par value.

Enquiries:

Thomas A Nicolette

President and Chief Executive Officer Tel: + 1 856 848 8698

Paul Shackleton/Emma Earl

Daniel Stewart & Company plc Tel: + 44 (0) 20 7776 6550

Ben Simons

M: Communications Tel: + 44 (0) 20 7920 2340

About Akers Biosciences, Inc.

Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. ABI has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com